These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Sustained administration of cyclazocine for antagonism of morphine. Sullivan MF; Ruemmler PS; Kalkwarf DR Drug Alcohol Depend; 1976 Oct; 1(6):415-28. PubMed ID: 1035154 [TBL] [Abstract][Full Text] [Related]
66. Polydimethylsiloxane pellets for sustained delivery of morphine in mice. Riffee WH; Wilcox RE; Anderson JA; McGinity JW J Pharm Sci; 1980 Aug; 69(8):980-2. PubMed ID: 7400953 [TBL] [Abstract][Full Text] [Related]
67. Letter To The Editor - Drug Eruption After Sustained Release Naltrexone Pellet Implantation. Ak S; Can Gürel Ş Turk Psikiyatri Derg; 2020; 31(2):146-147. PubMed ID: 32594504 [No Abstract] [Full Text] [Related]
68. Repeated administration of naltrexone produces tolerance to naloxone-induced hyperalgesia. Pilcher CW Life Sci; 1980 Nov; 27(20):1905-9. PubMed ID: 7464456 [No Abstract] [Full Text] [Related]
69. Plasma and semen kinetics of naltrexone in the rabbit. Taylor SM; Rodgers RM; Lynn RK; Gerber N Proc West Pharmacol Soc; 1979; 22():455-61. PubMed ID: 515087 [No Abstract] [Full Text] [Related]
70. Chronic naltrexone administration reverses the suppressive effect of crowding on body weight gain in rats. Amir S; Galina HZ; Amit Z Neuropharmacology; 1979 Nov; 18(11):905-7. PubMed ID: 551319 [No Abstract] [Full Text] [Related]
71. Biocompatibility and in vivo morphine diffusion into a placebo morphine-triggered naltrexone delivery device in rabbits. Roskos KV; Fritzinger BK; Tefft JA; Nakayama GR; Heller J Biomaterials; 1995 Nov; 16(16):1235-9. PubMed ID: 8589193 [TBL] [Abstract][Full Text] [Related]
72. A morphine-triggered delivery system useful in the treatment of heroin addiction. Roskos KV; Tefft JA; Heller J Clin Mater; 1993; 13(1-4):109-19. PubMed ID: 10146246 [TBL] [Abstract][Full Text] [Related]
73. Effect of naltrexone on relaxation induced by flank pressure in pigs. Grandin T; Dodman N; Shuster L Pharmacol Biochem Behav; 1989 Aug; 33(4):839-42. PubMed ID: 2616603 [TBL] [Abstract][Full Text] [Related]
74. Validation study of the conductometrical analysis. Application to the drug release studies from controlled release systems. Caraballo I; Alvarez-Fuentes J; Melgoza LM; Millán M; Holgado MA; Rabasco AM; Fernández-Arévalo M J Pharm Biomed Anal; 1998 Oct; 18(1-2):281-5. PubMed ID: 9863971 [No Abstract] [Full Text] [Related]
75. Sustained release of naltrexone from glyceride implants. Sullivan MF; Kalkward DR Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):27-32. PubMed ID: 1234982 [TBL] [Abstract][Full Text] [Related]
76. Development of polylactic/glycolic acid delivery systems for use in treatment of narcotic addiction. Schwope AD; Wise DL; Howes JF Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):13-8. PubMed ID: 787798 [TBL] [Abstract][Full Text] [Related]
77. Plasma corticosteroid levels in rats maintained on a long-acting naltrexone delivery system. Misra AL; Pontani RB; Vadlamani NL Res Commun Chem Pathol Pharmacol; 1978 Apr; 20(1):43-50. PubMed ID: 663407 [TBL] [Abstract][Full Text] [Related]
78. Use of synthetic polypeptides in the preparation of biodegradable delivery vehicles for narcotic antagonists. Sidman KR; Arnold DL; Steber WD; Nelsen L; Granchelli FE; Strong P; Sheth SG Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):33-8. PubMed ID: 1234983 [TBL] [Abstract][Full Text] [Related]
79. Sustained release of naltrexone from glyceride implants. Sullivan MF; Kalkwarf DR Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):27-32. PubMed ID: 967232 [TBL] [Abstract][Full Text] [Related]